Caplin Point Lab
Ticker > Company >

Caplin Point Lab share price

Caplin Point Laboratories Ltd.

NSE: CAPLIPOINT BSE: 524742 SECTOR: Pharmaceuticals & Drugs  2.32 L   1.64 K   253

2240.70
+4.10 (0.18%)
BSE: 12 Sep 04:01 PM

Price Summary

Today's High

₹ 2270.7

Today's Low

₹ 2225

52 Week High

₹ 2636

52 Week Low

₹ 1551.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 17031.94 Cr.

Enterprise Value

₹ 16817.23 Cr.

No. of Shares

7.6 Cr.

P/E

48.27

P/B

9.64

Face Value

₹ 2

Div. Yield

0.27 %

Book Value (TTM)

₹  232.49

CASH

₹ 214.71 Cr.

DEBT

₹ 0 Cr.

Promoter Holding

70.56 %

EPS (TTM)

₹  46.42

Sales Growth

20.37%

ROE

22.21 %

ROCE

28.58%

Profit Growth

19.66 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 19Indices.

NYMIDSML400MQ100

Nifty MidSmallcap400 Momentum Quality 100 Index
48783.1
  292.299999999996 (0.602794756943581%)

NFTSML250MOMQ100

Nifty Smallcap250 Momentum Quality 100 index
45832.15
  272.800000000003 (0.598779394350446%)

NFT500MOQ50

Nifty500 Multicap Momentum Quality 50 index
42067.1
  355.349999999999 (0.851918224481119%)

NFTSMLCAP250Q50

Nifty Smallcap250 Quality 50
26970.75
  40.9500000000007 (0.152062027939315%)

NIFTY500

Nifty 500
23190.25
  87.5999999999985 (0.379177280528409%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
19984.85
  58 (0.291064568659882%)

NIF500LGMIDSML

Nifty500 LargeMidSmall Equal-Cap Weighted Index
17832.35
  59.7999999999993 (0.336473944369264%)

NIFTYSMALLCAP250

Nifty Smallcap 250
17144.85
  54.3499999999985 (0.318012931160583%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
16163.75
  57.3999999999996 (0.356381178851817%)

NFT500EQUAL

Nifty 500 Equal Weight
14420.75
  39.0499999999993 (0.2715256193635%)

NIFTYTOTALMCAP

Nifty Total Market index
13051.25
  47 (0.361420304900317%)

SMLCAP

S&P Bse Small Cap
53548.49
  146.110000000001 (0.273602037961607%)

BSE HC

S&P Bse Healthcare
44922.57
  120.980000000003 (0.270035059023588%)

BSE500

S&P Bse 500
36418.62
  130.709999999999 (0.360202612936367%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
12414.1
  73.2299999999996 (0.593394144821224%)

MSL400

S&P Bse 400 MidSmallCap
12115.23
  24.6099999999988 (0.203546220127659%)

BSE1000

Bse 1000
10850.64
  36.4099999999999 (0.336686014630727%)

ALLCAP

S&P Bse Allcap
10130.99
  38.3799999999992 (0.380278243189802%)

SML250

S&P Bse 250 SmallCap
6862.99
  23.1899999999996 (0.33904500131583%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year20.37%
3 Year12.53%
5 Year7.35%

Profit Growth

1 Year19.66%
3 Year21.8%
5 Year11.43%

ROE%

1 Year22.21%
3 Year22.62%
5 Year22.79%

ROCE %

1 Year28.58%
3 Year28.61%
5 Year29.28%

Debt/Equity

0

Price to Cash Flow

86.96

Interest Cover Ratio

3681.5833

CFO/PAT (5 Yr. Avg.)

0.823587669363161

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 70.56 0.00
Mar 2025 70.56 0.00
Dec 2024 70.56 0.00
Sep 2024 70.56 0.00
Jun 2024 70.56 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 21.8025882507694% for the Past 3 years.
  • Company has been maintaining healthy ROE of 22.6237333333333% over the past 3 years.
  • Company has been maintaining healthy ROCE of 28.6106333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 3681.5833.
  • The Company has been maintaining an effective average operating margins of 43.3047285805463% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 3.77380000000001 days.
  • Company has a healthy liquidity position with current ratio of 8.2693.
  • The company has a high promoter holding of 70.56%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 55.5600699571412.

 Limitations

  • The company has shown a poor revenue growth of 12.5269592363449% for the Past 3 years.
  • The company is trading at a high PE of 48.27.
  • The company is trading at a high EV/EBITDA of 34.8674.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 185.64 207.93 185.23 173.61 182.57
Total Expenditure 104.26 109.77 107.84 98.57 95.96
Operating Profit 81.38 98.16 77.39 75.04 86.61
Other Income 21.5 43.01 28.83 41.25 32.03
Interest 0.02 0.02 0.04 0.04 0.04
Depreciation 6.18 6.49 6.01 6.09 6.14
Exceptional Items 0 0 0 0 0
Profit Before Tax 96.68 134.66 100.17 110.16 112.46
Tax 24.14 28.92 25.46 23.66 26.57
Profit After Tax 72.54 105.74 74.71 86.5 85.89
Adjusted EPS (Rs) 9.54 13.91 9.83 11.38 11.3

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 482.68 528.06 528.61 625.09 752.41
Total Expenditure 273.14 308.58 309.23 338.01 420.44
Operating Profit 209.54 219.48 219.38 287.08 331.97
Other Income 23.01 56.69 99.54 105.84 134.59
Interest 0.17 0.09 0.12 0.1 0.12
Depreciation 22.44 25.77 25.65 27.08 24.77
Exceptional Items 0 0 0 0 0
Profit Before Tax 209.94 250.31 293.15 365.74 441.67
Tax 53.71 62.44 58.89 82.03 102.18
Net Profit 156.23 187.87 234.26 283.71 339.49
Adjusted EPS (Rs.) 20.65 24.79 30.86 37.35 44.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 15.13 15.16 15.18 15.19 15.2
Total Reserves 743.54 915.49 1124.73 1374.96 1685.73
Borrowings 0 0 0 0 0
Other N/C liabilities 24.99 24.63 16.42 13.29 13.7
Current liabilities 77.33 98.88 146.85 118.87 99.85
Total Liabilities 860.99 1054.16 1303.18 1522.31 1814.48
Assets
Net Block 182.68 162.46 156.85 165.79 205.26
Capital WIP 1.36 1.73 42.68 27.75 20.64
Intangible WIP 0 0.87 0 0 0
Investments 138.64 212.73 274.97 346.17 491.11
Loans & Advances 5.67 70.7 164.7 272.07 257.13
Other N/C Assets 20 0 2.28 7.43 14.65
Current Assets 512.64 605.67 661.7 703.1 825.69
Total Assets 860.99 1054.16 1303.18 1522.31 1814.48
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 209.94 250.31 293.15 365.74 441.67
Adjustment 7.75 -19.43 -59.57 -68.57 -84.47
Changes in Assets & Liabilities 131.85 62.07 -11.45 -99.07 -57.49
Tax Paid -54.9 -61.98 -65.03 -87.09 -103.84
Operating Cash Flow 294.64 230.97 157.1 111.01 195.87
Investing Cash Flow -3.9 -276.02 -85.67 -118.13 -138.77
Financing Cash Flow -3.47 -22.76 -30.42 -34.26 -38.1
Net Cash Flow 287.27 -67.81 41.01 -41.38 19

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 70.56 70.56 70.56 70.56 70.56
ashok gorkey partheeban 11.91 11.91 11.91 11.91 11.91
first dimension holdings ... 0.49 0.49 0.49 0.49 0.49
kiraviz properties and co... 0.20 0.20 0.20 0.20 0.20
may india property privat... 2.79 2.79 2.79 2.79 2.79
p vijayalakshmi 24.71 24.71 24.71 24.71 24.71
paarthipan c c 18.64 18.64 18.64 18.64 18.64
partheeban vivek siddarth... 11.84 11.84 11.84 11.84 11.84
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 29.44 29.44 29.44 29.44 29.44
investor education and pr... - - - - 2.73
llp 0.52 0.50 0.49 0.49 0.53
uti multi cap fund - - - - 1.49
investor education and pr... 2.72 2.71 2.76 2.74 -
uti small cap fund 1.21 1.47 1.39 1.27 -
foreign portfolio inv1&2 - - 0.02 - -
suresh kumar agarwal 1.32 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research HDFC Securities
Research HDFC Securities
Research HDFC Securities
Research Ventura

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q3FY24
Concall Q3FY21
Concall Q3FY19
Concall Q2FY24
Concall Q2FY24
Concall Q2FY21
Concall Q1FY24
Concall Q1FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY20
Presentation Q3FY24
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY21
Presentation Q2FY20
Presentation Q1FY24
Presentation Q1FY21

Company News

Caplin Point’s arm gets USFDA’s final nod for Milrinone Lactate in 5% Dextrose Injection 3 Sep, 4:14 PM Caplin Point Laboratories informs about press release 3 Sep, 3:42 PM Caplin Point Laboratories reports 23% rise in Q1 consolidated net profit 7 Aug, 3:36 PM Caplin Point Lab - Quaterly Results 7 Aug, 12:54 PM Caplin Point Lab - Quaterly Results 7 Aug, 12:54 PM Caplin Point Lab - Quaterly Results 7 Aug, 12:54 PM Caplin Point Laboratories informs about analyst meet 30 Jul, 2:45 PM Caplin Point Laboratories’ arm executes SPA to acquire entire stake in Triwin Pharma 4 Jun, 3:41 PM Caplin Point Lab - Quaterly Results 15 May, 1:42 PM Caplin Point Lab - Quaterly Results 15 May, 1:42 PM Caplin Point Lab - Quaterly Results 15 May, 1:42 PM Caplin Point’s arm gets USFDA’s final nod for Haloperidol Decanoate Injection 14 May, 2:28 PM Caplin Point Laboratories informs about financial results 7 May, 5:11 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Phytonadione Injectable Emulsion 23 Apr, 3:18 PM Caplin Point Laboratories informs about press release 23 Apr, 12:31 PM Caplin Point Laboratories’ arm acquires Neoethicals Chile SpA 2 Apr, 5:05 PM Caplin Point’s arm gets USFDA’s final nod for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution 27 Feb, 9:37 AM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Lab - Quaterly Results 7 Feb, 1:15 PM Caplin Point Laboratories informs about press release 5 Feb, 2:50 PM Caplin Point’s arm gets USFDA’s approval for Procainamide Hydrochloride Injection 5 Feb, 12:20 PM Caplin Point’s arm gets USFDA’s approval for Levetiracetam in Sodium Chloride Injection, infusion bags 17 Jan, 2:28 PM Caplin Point Laboratories receives EIR from USFDA 7 Jan, 10:59 AM Caplin Point Laboratories informs about press release 16 Dec, 5:22 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Difluprednate Ophthalmic Emulsion 16 Dec, 12:48 PM Caplin Point Laboratories informs about loss of share certificate 12 Dec, 2:37 PM Caplin Point Laboratories informs about loss of share certificate 15 Nov, 4:54 PM Caplin Point Lab - Quaterly Results 7 Nov, 1:42 PM Caplin Point Lab - Quaterly Results 7 Nov, 1:42 PM Caplin Point Lab - Quaterly Results 7 Nov, 1:42 PM Caplin Point Laboratories informs about certificate 10 Oct, 4:26 PM ANVISA-Brazil concludes inspection at manufacturing facility of Caplin Point’s arm 17 Aug, 4:29 PM USFDA completes unannounced inspection at Caplin Point’s arm’s manufacturing facility in Tamil Nadu 10 Aug, 10:26 AM Caplin Point Laboratories informs about press release 8 Aug, 1:11 PM Caplin Point Laboratories’ arm gets USFDA’s final nod for Timolol Maleate Ophthalmic Solution 8 Aug, 1:07 PM Caplin Point Lab - Quaterly Results 7 Aug, 1:05 PM Caplin Point Lab - Quaterly Results 7 Aug, 1:05 PM Caplin Point Lab - Quaterly Results 7 Aug, 1:05 PM Caplin Point Laboratories’ arm gets USFDA’s approval for Ephedrine Sulfate Injection 19 Jul, 11:28 AM Caplin Point Laboratories informs about loss of share certificate 24 Jun, 12:17 PM Caplin Point Laboratories informs about press release 24 May, 1:03 PM Caplin Point’s arm gets USFDA’s approval for Phenylephrine Hydrochloride Ophthalmic Solution 24 May, 11:27 AM Caplin Point Lab - Quaterly Results 16 May, 1:55 PM Caplin Point Lab - Quaterly Results 16 May, 1:55 PM Caplin Point Lab - Quaterly Results 16 May, 1:55 PM Caplin Point gets Colombia's INVIMA approval for Softgel Capsules division 6 May, 11:40 AM Caplin Point Laboratories informs about press release 16 Apr, 2:49 PM Caplin Point Laboratories’ arm gets final approval from USFDA for Ofloxacin Ophthalmic Solution 16 Apr, 12:30 PM Caplin Point Laboratories informs about press release 28 Mar, 12:37 PM

Caplin Point Lab Stock Price Analysis and Quick Research Report. Is Caplin Point Lab an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Caplin Point Lab. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Caplin Point Lab has a PE ratio of 48.3765338480629 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Caplin Point Lab has ROA of 20.3483% which is a good sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Caplin Point Lab has a Current ratio of 8.2693.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Caplin Point Lab has a ROE of 22.2091%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Caplin Point Lab has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: Caplin Point Lab has reported revenue growth of 20.3683% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Caplin Point Lab for the current financial year is 44.1208915352002%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Caplin Point Lab is Rs 6 and the yield is 0.2678%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Caplin Point Lab is Rs 46.4192. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Caplin Point Lab in Ticker for free. Also, one can get the intrinsic value of Caplin Point Lab by using Valuation Calculators, which are available with a Finology ONE subscription. 

Caplin Point Lab FAQs

Q1. What is Caplin Point Lab share price today?
Ans: The current share price of Caplin Point Lab is Rs 2245.6.

Q2. What is the market capitalisation of Caplin Point Lab?
Ans: Caplin Point Lab has a market capitalisation of Rs 17069.18645376 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Caplin Point Lab?
Ans: The PE ratio of Caplin Point Lab is 48.3765338480629 and the P/B ratio of Caplin Point Lab is 9.65898484310171, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Caplin Point Lab share?
Ans: The 52-week high share price of Caplin Point Lab is Rs 2641, and the 52-week low share price of Caplin Point Lab is Rs 1599.

Q5. Does Caplin Point Lab pay dividends?
Ans: Currently, Caplin Point Lab pays dividends. Dividend yield of Caplin Point Lab is around 0.2678%.

Q6. What are the face value and book value of Caplin Point Lab shares?
Ans: The face value of Caplin Point Lab shares is Rs 2, while the book value per share of Caplin Point Lab is around Rs 232.4882. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Caplin Point Lab?
Ans: Caplin Point Lab has a total debt of Rs 0 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Caplin Point Lab?
Ans: The ROE of Caplin Point Lab is 22.2091% and ROCE of Caplin Point Lab is 28.5848%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Caplin Point Lab a good buy for the long term?
Ans: The Caplin Point Lab long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Caplin Point Lab undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Caplin Point Lab appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Caplin Point Lab’s financials?
Ans: You can review Caplin Point Lab’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Caplin Point Lab

Caplin Point Laboratories Ltd. Financials: Check Share price, Balance Sheet, Annual report and Quarterly Results for company analysis

Welcome to our website and our comprehensive analysis of Caplin Point Laboratories Ltd. for long-term stock investors looking for detailed insights and information about the company's performance and potential. On our website, we provide a wide range of tools and features to empower investors, including pre-built screening tools and premium analysis tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Caplin Point Laboratories Ltd.Share Price Analysis:

Analyzing the historical share prices of Caplin Point Laboratories Ltd. is vital for long-term investors striving to understand the stock's performance over time. By monitoring share prices, investors can identify trends and patterns that may influence their investment decisions. On the ticker website, we provide an accurate and up-to-date analysis of Caplin Point Laboratories Ltd.'s share prices, accompanied by interactive price charts, to assist investors in monitoring the stock's performance and identifying potential entry and exit points. A stock's share price is determined by a range of factors such as market sentiment, financial performance, and general economic conditions.

Caplin Point Laboratories Ltd.Balance Sheet:

Analyzing the balance sheet of Caplin Point Laboratories Ltd. is essential in gauging the company's financial health and stability, evaluating the quality of earnings, and assessing the sustainability of growth for long-term investors. On the ticker website, we provide Caplin Point Laboratories Ltd.'s balance sheet for thorough analysis, enabling investors to make well-informed investment decisions based on the company's financial position.

Caplin Point Laboratories Ltd.Annual Report:

Caplin Point Laboratories Ltd.'s annual report provides detailed insights into the company's performance, strategies, and future outlook. This report includes information about the company's business operations, financials, and corporate governance practices. For long-term investors, reviewing the annual report is highly recommended as it offers valuable insights into the company's growth prospects and helps assess its potential for generating sustainable returns. On ticker website, investors can conveniently access and download the annual reports of Caplin Point Laboratories Ltd. for in-depth analysis.

Caplin Point Laboratories Ltd.Dividend Analysis:

Caplin Point Laboratories Ltd. has consistently rewarded its investors through dividends, making tracking its dividend payments and announcements crucial in understanding the company's financial performance. By analyzing historical dividend payments and announcements of Caplin Point Laboratories Ltd. on our website, investors can monitor the company's dividend-paying track record using our user-friendly interface.

Caplin Point Laboratories Ltd.Quarterly Result Evaluation:

Keeping track of the quarterly results of Caplin Point Laboratories Ltd. is paramount for long-term investors. Quarterly reports offer insights into the company's revenue, earnings, and relevant financial metrics. On our website, investors can easily download quarterly reports of Caplin Point Laboratories Ltd. for thorough analysis. By studying these reports, investors can gain a comprehensive understanding of the company's financial performance over time, enabling better decision-making when it comes to long-term investments.

Caplin Point Laboratories Ltd.Stock Price Analysis:

Analyzing the price movement of Caplin Point Laboratories Ltd.'s stock is a critical tool for long-term investors. Our website provides detailed price charts that assist investors in identifying trends and patterns in the stock's performance. By studying the historical price movements, investors can identify potential entry and exit points. Paired with our pre-built screening tools, investors can make well-informed decisions based on thorough analysis of Caplin Point Laboratories Ltd.'s stock price. Our website provides pre-built screening tools to help investors analyze stock price and performance.

Caplin Point Laboratories Ltd.Price Chart Analysis:

On our website, investors can access interactive price charts that visually represent the historical movement of Caplin Point Laboratories Ltd.'s stock price. These charts enable investors to identify patterns, trends, and potential opportunities based on the stock's performance. By analyzing the price chart, investors can enhance their understanding of the stock's behavior, and couple it with our pre-built screening tools to make informed investment decisions.

Caplin Point Laboratories Ltd.News Coverage

Staying updated on the latest news and developments related to Caplin Point Laboratories Ltd. is crucial for investors. Our website provides regular news updates related to the company, including company announcements, industry trends, and macroeconomic factors that may impact the stock price. By staying informed, investors can make well-informed decisions based on the most current and relevant information available.

Caplin Point Laboratories Ltd.Conference Call Transcripts:

Conference call transcripts provide in-depth insights into the company's management discussions and interactions with analysts during important conference calls. On our website, investors can conveniently download the transcripts of Caplin Point Laboratories Ltd.'s conference calls, providing valuable knowledge about the company's strategic direction, future plans, and management outlook. By studying these transcripts, investors can gain a comprehensive understanding of Caplin Point Laboratories Ltd.'s performance and prospects.

Caplin Point Laboratories Ltd.Investor Presentations:

Caplin Point Laboratories Ltd. conducts investor presentations to provide an overview of its operations, financial performance, and growth prospects. These presentations offer insights into the company's strategies and initiatives, providing a clearer understanding of the company's goals and direction. On our website, investors can access Caplin Point Laboratories Ltd.'s investors presentations, ensuring they stay informed about the company's initiatives, understand its long-term vision, and assess its potential for generating sustainable returns. These presentations can be complemented and analyzed using our premium analysis tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Caplin Point Laboratories Ltd.Promoters

The promoters of Caplin Point Laboratories Ltd. play a critical role in the company's management and decision-making processes. As an investor, understanding the background and track record of the promoters is essential in gauging their contributions to the company's success. On the ticker website, investors can find valuable information about the promoters of Caplin Point Laboratories Ltd., enabling them to assess their contributions to the company and make well-informed decisions based on comprehensive analysis.

Caplin Point Laboratories Ltd.Shareholders

Understanding the major shareholders of Caplin Point Laboratories Ltd. is critical in assessing the company's ownership structure and potential influences on decision-making. Ticker website provides a detailed breakdown of major shareholders, including institutional and retail ownership. This information helps investors gauge the level of ownership concentration in the stock and evaluate potential risks and opportunities associated with the company's ownership dynamics.

Caplin Point Laboratories Limited ROCE

Caplin Point Laboratories Limited's ROCE (Return on Capital Employed) is a financial metric that measures how efficiently a company is using its capital to generate profits. This ratio is an essential indicator of a company's profitability, as it measures how much profit a company is making from the capital it has invested. You can find Caplin Point Laboratories Limited's ROCE data in the financials table or ratio section.

Caplin Point Laboratories Limited EBITDA

EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a financial ratio that evaluates a company's operating performance. It measures the company's earnings before accounting for the effects of interest, taxes, depreciation, and amortization. Caplin Point Laboratories Limited's EBITDA can be found in the financials table or ratio section.

Caplin Point Laboratories Limited DPS

DPS (Dividend Per Share) is a financial metric that shows how much a company is paying its shareholders per share. Dividends are distributed to the shareholders as a portion of a company's profits. Caplin Point Laboratories Limited's DPS can be found in the financials table or ratio section.

Caplin Point Laboratories Limited EPS

EPS (Earnings Per Share) is a financial metric that measures the amount of earnings per share of a company's common stock. It is calculated by dividing a company's net earnings by the total number of shares outstanding. Caplin Point Laboratories Limited's EPS can be found in the financials table or ratio section.

In conclusion, Caplin Point Laboratories Limited's stock analysis page provides key financial metrics necessary for analyzing a company's performance in the stock market. These metrics can help investors make informed decisions about investing in the company. 

Caplin Point Laboratories Balance Sheet Evolution

Caplin Point Laboratories' Share Capital Stability

Caplin Point Laboratories has maintained a stable share capital from March 2020 (Rs 15.13 Cr) with a slight increase by March 2024 to Rs 15.19 Cr. This consistency reflects the company's stable financing strategy and shareholder confidence.

Rise in Reserves at Caplin Point Laboratories

There is a notable increase in the total reserves of Caplin Point Laboratories, ascending from Rs 584.78 Cr in March 2020 to Rs 1,374.96 Cr in March 2024. The robust growth in reserves underscores the company's profitability and financial health.

Caplin Point Laboratories' Minimal Borrowings

Caplin Point Laboratories exhibited nearly zero borrowings from March 2021 onwards, showcasing the company's strong liquidity position and its ability to fund operations without leveraging.

Caplin Point Laboratories' Asset Growth

The asset growth journey of Caplin Point Laboratories showcases a total asset increase from Rs 691.33 Cr in March 2020 to Rs 1,522.31 Cr by March 2024. This growth signifies an enhancement in operational capabilities and asset acquisition for future ventures.

This data represents an analysis of the standalone balance sheet of Caplin Point Laboratories and provides insights into its financial stature over the years. Analysis like this can benefit investors exploring opportunities in the healthcare sector across various market environments, including the NSE BSE indices.

Read More
X